Antioxidant and lipid-regulating effects of probucol combined with atorvastatin in patients with acute coronary syndrome

Journal of Thoracic Disease

Volumn 7, Issue 3, 2015, Pages 368-375

  Guo, Yu Song ^a   Wang, Cai Xia ^a   Cao, Jian ^a   Gao, Jin Liao ^a   Zou, Xiao ^a   Ren, Yi Hong ^a   Fan, Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Acute coronary syndrome (ACS); Atorvastatin; Oxidized low density lipoprotein (ox LDL); Paraoxonase 1 (PON1); Probucol

Indexed keywords

ANTITHROMBOCYTIC AGENT; ARYLDIALKYLPHOSPHATASE 1; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PROBUCOL; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; AGE; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROTEIN EXPRESSION; SEX DIFFERENCE; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84928606310     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2014.12.29     Document Type: Article

References (32)

1. Ge CJ, Lü SZ, Feng LX, et al. Combined effect of atorvastatin and probucol on plasma cystatin C levels and severity of coronary lesion in patients with borderline coronary lesion. Chin Med J (Engl) 2012;125:2472-6.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
3. Zhou C, Cao J, Shang L, et al. Reduced paraoxonase 1 activity as a marker for severe coronary artery disease. Dis Markers 2013;35:97-103.
4. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005;25:29-38.
5. Miyauchi K, Morino Y, Tsukahara K, et al. The PACIFIC (Prevention of AtherothrombotiC Incidents Following Ischemic Coronary attack) Registry: Rationale and design of a 2-year study in patients initially hospitalised with acute coronary syndrome in Japan. Cardiovasc Drugs Ther 2010;24:77-83.
6. Ho E, Karimi Galougahi K, Liu CC, et al. Biological markers of oxidative stress: Applications to cardiovascular research and practice. Redox Biol 2013;1:483-91.
7. Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond) 2009;116:87-98.
8. Mascarenhas-Melo F, Sereno J, Teixeira-Lemos E, et al. Implication of low HDL-c levels in patients with average LDL-c levels: a focus on oxidized LDL, large HDL subpopulation, and adiponectin. Mediators Inflamm 2013;2013:612038.
9. Mackness B, Mackness M. Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Adv Exp Med Biol 2010;660:143-51.
10. Huang Y, Wu Z, Riwanto M, et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 2013;123:3815-28.
11. Inagaki M, Nakagawa-Toyama Y, Nishida M, et al. Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2012;19:643-56.
12. Zhong JK, Guo ZG, Li C, et al. Probucol alleviates atherosclerosis and improves high density lipoprotein function. Lipids in Health and Disease 2011;10:210.
13. Scheffer PG, Schindhelm RK, van Verschuer VM, et al. No effect of atorvastatin and simvastatin on oxidative stress in patients at high risk for cardiovascular disease. Neth J Med 2013;71:359-65.
14. Zhou Q, Liao JK. Pleiotropic effects of statins. - Basic research and clinical perspectives. Circ J 2010;74:818-26.
15. Yasuda G, Ando D, Hirawa N, et al. Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy. Ren Fail 2010;32:680-6.
16. Karimi P, Rashtchizadeh N. Oxidative Versus Thrombotic Stimulation of Platelets Differentially activates Signalling Pathways. J Cardiovasc Thorac Res 2013;5:61-5.
17. Tumova E, Sun W, Jones PH, et al. The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. J Obes 2013;2013:729515.
18. Shekhanawar M, Shekhanawar SM, Krisnaswamy D, et al. The role of 'paraoxonase-1 activity' as an antioxidant in coronary artery diseases. J Clin Diagn Res 2013;7:1284-7.
19. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-80.
20. Yamamoto A. A uniqe antilipidemic drug-probucol. J Atheroscler Thromb 2008;15:304-5.
21. Yamashita S, Hbujo H, Arai H, et al. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 2008;15:292-303.
22. Inagaki M, Nakagawa-Toyama Y, Nishida M, et al. Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2012;19:643-56.
23. Sawayama Y, Shimizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002;39:610-6.
24. Nagila A, Permpongpaiboon T, Tantrarongroj S, et al. Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacol Rep 2009;61:892-8.
25. Yeung AC, Tsao P. Statin therapy: beyond cholesterol lowering and antiinflammatory effects. Circulation 2002;105:2937-8.
26. Kural BV, Orem C, Uydu HA, et al. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. Coron Artery Dis 2004;15:277-83.
27. Hong SC, Zhao SP, Wu ZH. Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits. J Cardiovasc Pharmacol 2006;47:77-81.
28. Razavi AE, Ani M, Pourfarzam M, et al. Associations between high density lipoprotein mean particle size and serum paraoxonase-1 activity. J Res Med Sci 2012;17:1020-6.
29. Long X, Li XP, Xue YQ, et al. The lipid modulation and antioxidant effect of probucol and atorvastatin combination in patients with acute coronary syndrome. Chinese Journal of Arteriosclerosis 2009;17:933-7.
30. Harangi M, Mirdamadi HZ, Seres I, et al. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity. Transl Res 2009;153:190-8.
31. Whayne TF Jr. Problems and possible solutions for therapy with statins. Int J Angiol 2013;22:75-82.
32. Taha DA, De Moor CH, Barrett DA, et al. Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. Transl Res 2014;164:85-109.